Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE)
Naomi Wijesingha, Aachal Kotecha, Philippe Margaron, Sobha Sivaprasad · 2024
Read Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE) by Naomi Wijesingha, Aachal Kotecha, Philippe Margaron, Sobha Sivaprasad (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11621683.txt.
Description
nd-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE)”, written by Naomi Wijesingha, Aachal Kotecha, Philippe Margaron and Sobha Sivaprasad, was originally published electronically on the publisher’s internet portal on 10 July 2024 without open access.
Catalog record
| CREATOR | Naomi Wijesingha, Aachal Kotecha, Philippe Margaron, Sobha Sivaprasad |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |